14 Citations (Scopus)

Abstract

ABSTRACT: Introduction: Microtubules represent one of the most logical and strategic molecular targets amongst the current targets for chemotherapy, alongside DNA. In the past decade, tubulin inhibitors as cancer therapeutics have been an area of focus due to the improved understanding and biological relevance of microtubules in cellular functions. Fueled by the objective of developing novel chemotherapeutics and with the aim of establishing the benefits of tubulin inhibition, several clinical trials have been conducted with others ongoing. Area covered: At present, the antitubulin development pipeline contains an armful of agents under clinical investigation. This review focuses on novel tubulin inhibitors as cancer therapeutics. The article covers the agents which have completed the phase II studies along with the agents demonstrating promising results in phase I studies. Expert opinion: Countless clinical trials evaluating the efficacy, safety and pharmacokinetics of novel tubulin inhibitors highlights the scientific efforts being paid to establish their candidature as cancer therapeutics. Colchicine binding site inhibitors as vascular disrupting agents (VDAs) and new taxanes appear to be the most likely agents for future clinical interest. Numerous agents have demonstrated clinical benefits in terms of efficacy and survival in phase I and II studies. However conclusive benefits can only be ascertained on the basis of phase III studies.

Original languageEnglish
Pages (from-to)917-936
Number of pages20
JournalExpert Opinion on Investigational Drugs
Volume25
Issue number8
DOIs
Publication statusPublished - Aug 2 2016

Fingerprint

Tubulin Modulators
Microtubules
Clinical Trials
Taxoids
Neoplasms
Colchicine
Expert Testimony
Tubulin
Blood Vessels
Therapeutics
Pharmacokinetics
Binding Sites
Safety
Drug Therapy
DNA

Keywords

  • colchicine
  • efficacy
  • microtubules
  • objective response
  • overall survival
  • progression free survival
  • solid tumors
  • taxanes
  • Tubulin inhibitors

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Early investigational tubulin inhibitors as novel cancer therapeutics. / Nepali, Kunal; Ojha, Ritu; Lee, Hsueh Yun; Liou, Jing Ping.

In: Expert Opinion on Investigational Drugs, Vol. 25, No. 8, 02.08.2016, p. 917-936.

Research output: Contribution to journalReview article

@article{54e16d8ec5d14ea5a6fedd705cbf918e,
title = "Early investigational tubulin inhibitors as novel cancer therapeutics",
abstract = "ABSTRACT: Introduction: Microtubules represent one of the most logical and strategic molecular targets amongst the current targets for chemotherapy, alongside DNA. In the past decade, tubulin inhibitors as cancer therapeutics have been an area of focus due to the improved understanding and biological relevance of microtubules in cellular functions. Fueled by the objective of developing novel chemotherapeutics and with the aim of establishing the benefits of tubulin inhibition, several clinical trials have been conducted with others ongoing. Area covered: At present, the antitubulin development pipeline contains an armful of agents under clinical investigation. This review focuses on novel tubulin inhibitors as cancer therapeutics. The article covers the agents which have completed the phase II studies along with the agents demonstrating promising results in phase I studies. Expert opinion: Countless clinical trials evaluating the efficacy, safety and pharmacokinetics of novel tubulin inhibitors highlights the scientific efforts being paid to establish their candidature as cancer therapeutics. Colchicine binding site inhibitors as vascular disrupting agents (VDAs) and new taxanes appear to be the most likely agents for future clinical interest. Numerous agents have demonstrated clinical benefits in terms of efficacy and survival in phase I and II studies. However conclusive benefits can only be ascertained on the basis of phase III studies.",
keywords = "colchicine, efficacy, microtubules, objective response, overall survival, progression free survival, solid tumors, taxanes, Tubulin inhibitors, colchicine, efficacy, microtubules, objective response, overall survival, progression free survival, solid tumors, taxanes, Tubulin inhibitors",
author = "Kunal Nepali and Ritu Ojha and Lee, {Hsueh Yun} and Liou, {Jing Ping}",
year = "2016",
month = "8",
day = "2",
doi = "10.1080/13543784.2016.1189901",
language = "English",
volume = "25",
pages = "917--936",
journal = "Expert Opinion on Investigational Drugs",
issn = "1354-3784",
publisher = "Informa Healthcare",
number = "8",

}

TY - JOUR

T1 - Early investigational tubulin inhibitors as novel cancer therapeutics

AU - Nepali, Kunal

AU - Ojha, Ritu

AU - Lee, Hsueh Yun

AU - Liou, Jing Ping

PY - 2016/8/2

Y1 - 2016/8/2

N2 - ABSTRACT: Introduction: Microtubules represent one of the most logical and strategic molecular targets amongst the current targets for chemotherapy, alongside DNA. In the past decade, tubulin inhibitors as cancer therapeutics have been an area of focus due to the improved understanding and biological relevance of microtubules in cellular functions. Fueled by the objective of developing novel chemotherapeutics and with the aim of establishing the benefits of tubulin inhibition, several clinical trials have been conducted with others ongoing. Area covered: At present, the antitubulin development pipeline contains an armful of agents under clinical investigation. This review focuses on novel tubulin inhibitors as cancer therapeutics. The article covers the agents which have completed the phase II studies along with the agents demonstrating promising results in phase I studies. Expert opinion: Countless clinical trials evaluating the efficacy, safety and pharmacokinetics of novel tubulin inhibitors highlights the scientific efforts being paid to establish their candidature as cancer therapeutics. Colchicine binding site inhibitors as vascular disrupting agents (VDAs) and new taxanes appear to be the most likely agents for future clinical interest. Numerous agents have demonstrated clinical benefits in terms of efficacy and survival in phase I and II studies. However conclusive benefits can only be ascertained on the basis of phase III studies.

AB - ABSTRACT: Introduction: Microtubules represent one of the most logical and strategic molecular targets amongst the current targets for chemotherapy, alongside DNA. In the past decade, tubulin inhibitors as cancer therapeutics have been an area of focus due to the improved understanding and biological relevance of microtubules in cellular functions. Fueled by the objective of developing novel chemotherapeutics and with the aim of establishing the benefits of tubulin inhibition, several clinical trials have been conducted with others ongoing. Area covered: At present, the antitubulin development pipeline contains an armful of agents under clinical investigation. This review focuses on novel tubulin inhibitors as cancer therapeutics. The article covers the agents which have completed the phase II studies along with the agents demonstrating promising results in phase I studies. Expert opinion: Countless clinical trials evaluating the efficacy, safety and pharmacokinetics of novel tubulin inhibitors highlights the scientific efforts being paid to establish their candidature as cancer therapeutics. Colchicine binding site inhibitors as vascular disrupting agents (VDAs) and new taxanes appear to be the most likely agents for future clinical interest. Numerous agents have demonstrated clinical benefits in terms of efficacy and survival in phase I and II studies. However conclusive benefits can only be ascertained on the basis of phase III studies.

KW - colchicine

KW - efficacy

KW - microtubules

KW - objective response

KW - overall survival

KW - progression free survival

KW - solid tumors

KW - taxanes

KW - Tubulin inhibitors

KW - colchicine

KW - efficacy

KW - microtubules

KW - objective response

KW - overall survival

KW - progression free survival

KW - solid tumors

KW - taxanes

KW - Tubulin inhibitors

UR - http://www.scopus.com/inward/record.url?scp=84978701854&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978701854&partnerID=8YFLogxK

U2 - 10.1080/13543784.2016.1189901

DO - 10.1080/13543784.2016.1189901

M3 - Review article

C2 - 27186892

AN - SCOPUS:84978701854

VL - 25

SP - 917

EP - 936

JO - Expert Opinion on Investigational Drugs

JF - Expert Opinion on Investigational Drugs

SN - 1354-3784

IS - 8

ER -